Revised Statement of Deviation or Variation
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Magenta Lifecare Ltd has confirmed to the BSE that there is no deviation or variation in the use of its IPO proceeds for the half-year ended 30th September 2025. The company had raised Rs. 5.98 crore through a public issue on 10th June 2024, which was earmarked for two purposes: Rs. 424 lakhs for incremental working capital requirements and Rs. 174 lakhs for general corporate purposes. Both allocations have been fully utilised exactly as originally disclosed, with zero deviation. The Audit Committee and auditors have raised no comments on the fund usage. This is a routine compliance filing under SEBI's listing regulations.
This is a neutral-to-slightly positive disclosure — it reassures shareholders that the company has used IPO funds strictly as promised in its prospectus, with no misuse or reallocation. For retail investors, this signals good governance and transparency, though it carries no direct impact on stock price or near-term business outlook.